Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Modalis Therapeutics Corporation
No Price
Closing Price XTKS 28.04.2026:
66,00 JPY
28.04.2026 06:30
Current Prices from Modalis Therapeutics Corporation
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
Tokyo
4883.T
JPY
28.04.2026 06:30
66,00 JPY
12,00 JPY
+22,22 %
Share Float & Liquidity
Free Float96,25 %
Shares Float83,42 M
Shares Outstanding86,67 M
Company Profile for Modalis Therapeutics Corporation Share
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd. to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan.
